AAV-FGF21

AAV-FGF21 has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Oct 29, 2026: “Gene therapy extended lifespan with health benefits in mice”.

Intervention

1 paper studies it5 findingsUpdated

See all 1

None of its findings points the other way.

  • 1 lab in 1 country
  • Funders: Agencia Estatal de Investigación and 6 more
  • 5 of 5 findings with company ties
  • Animals1

What did studies of AAV-FGF21 find?

5

Studies of AAV-FGF21 measured 5 outcomes; the most studied are AMPK signaling (1 study), kidney disease (1) and cognitive function (1).

AMPK signaling

upin mice1

1 study
  1. AAV-FGF21 activates AMPK signaling in mice.

    “AAV-FGF21 treatment also activated AMPK signaling.”

    Animals

    Gene therapy extended lifespan with health benefits in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

More on AMPK signaling

Kidney disease

downin mice1

1 study
  1. AAV-FGF21 protects against kidney disease in mice.

    “counteracted age-related kidney disease”

    Animals

    Gene therapy extended lifespan with health benefits in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

More on Kidney disease

Cognitive function

upin mice1

1 study
  1. AAV-FGF21 improves cognitive function in mice.

    “promoted cardiac health and muscular function, and enhanced cognition.”

    Animals

    Gene therapy extended lifespan with health benefits in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

Healthspan

upin mice1

1 study
  1. AAV-FGF21 improves healthspan in mice.

    “treated with muscle-directed adeno-associated viral (AAV) vector-mediated fibroblast growth factor 21 (FGF21) gene therapy extended health span and lifespan”

    Animals

    Gene therapy extended lifespan with health benefits in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

Lifespan

upin mice1

1 study
  1. AAV-FGF21 extends lifespan in mice.

    “treated with muscle-directed adeno-associated viral (AAV) vector-mediated fibroblast growth factor 21 (FGF21) gene therapy extended health span and lifespan”

    Animals

    Gene therapy extended lifespan with health benefits in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 01 paper in 12 months
Molecular Therapy

Gene therapy extended lifespan with health benefits in mice

Male mice treated at 13 months had a median lifespan of 33.92 months, compared with 28.14 months in controls.Male mice treated at 13 months had a median lifespan of 33.92 months, compared with 28.14 months in controls.

Mouse studyInterventions